Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action.

Fibroblast growth factor 1 (FGF-1) shows strong angiogenic, osteogenic and tissue-injury repair properties that might be relevant to medical applications. Since FGF-1 is partially unfolded at physiological temperature we decided to increase significantly its conformational stability and test how such an improvement will affect its biological function. Using an homology approach and rational strategy we designed two new single FGF-1 mutations: Q40P and S47I that appeared to be the most strongly stabilizing substitutions among those reported so far, increasing the denaturation temperature by 7.8 deg. C and 9.0 deg. C, respectively. As our goal was to produce highly stable variants of the growth factor, we combined these two mutations with five previously described stabilizing substitutions. The multiple mutants showed denaturation temperatures up to 27 deg. C higher than the wild-type and exhibited full additivity of the mutational effects. All those mutants were biologically competent in several cell culture assays, maintaining typical FGF-1 activities, such as binding to specific cell surface receptors and activation of downstream signaling pathways. Thus, we demonstrate that the low denaturation temperature of wild-type FGF-1 is not related to its fundamental cellular functions, and that FGF-1 action is not affected by its stability. A more detailed analysis of the biological behavior of stable FGF-1 mutants revealed that, compared with the wild-type, their mitogenic properties, as probed by the DNA synthesis assay, were significantly increased in the absence of heparin, and that their half-lives were extensively prolonged. We found that the biological action of the mutants was dictated by their susceptibility to proteases, which strongly correlated with the stability. Mutants which were much more resistant to proteolytic degradation always displayed a significant improvement in the half-life and mitogenesis. Our results show that engineered stable growth factor variants exhibit enhanced and prolonged activity, which can be advantageous in terms of the potential therapeutic applications of FGF-1.

[1]  P. Privalov,et al.  Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Jacek Otlewski,et al.  Analysis of serine proteinase–inhibitor interaction by alanine shaving , 2002, Protein science : a publication of the Protein Society.

[3]  R. Kaufman,et al.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Volkin,et al.  Partially structured self-associating states of acidic fibroblast growth factor. , 1993, Biochemistry.

[5]  Brian W. Matthews,et al.  Refinement of the structure of human basic fibroblast growth factor at 1.6 Å resolution and analysis of presumed heparin binding sites by selenate substitution , 1993, Protein science : a publication of the Protein Society.

[6]  R. Sauer,et al.  The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. , 1989, The Journal of biological chemistry.

[7]  O. Ptitsyn,et al.  The ‘molten globule’ state is involved in the translocation of proteins across membranes? , 1988, FEBS letters.

[8]  L. Rue,et al.  Site-specific delivery of acidic fibroblast growth factor stimulates angiogenic and osteogenic responses in vivo. , 2004, Journal of biomedical materials research. Part A.

[9]  A. Fersht,et al.  Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Maciag,et al.  The Nuclear Trafficking of Extracellular Fibroblast Growth Factor (FGF)-1 Correlates with the Perinuclear Association of the FGF Receptor-1α Isoforms but Not the FGF Receptor-1β Isoforms* , 1996, The Journal of Biological Chemistry.

[11]  B. Luxon,et al.  Pegylated interferons for the treatment of chronic hepatitis C infection. , 2002, Clinical therapeutics.

[12]  M. Blaber,et al.  Reversible thermal denaturation of human FGF-1 induced by low concentrations of guanidine hydrochloride. , 1999, Biophysical journal.

[13]  M. Blaber,et al.  Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life. , 2000, Biochemistry.

[14]  Anirban Kundu,et al.  Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening , 2002, Protein science : a publication of the Protein Society.

[15]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[16]  W H Burgess,et al.  The mitogenic activity of fibroblast growth factor‐1 correlates with its internalization and limited proteolytic processing , 2000, Journal of cellular physiology.

[17]  G. Giménez-Gallego,et al.  Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor. , 1991, The Journal of biological chemistry.

[18]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[19]  A. Halfpenny,et al.  The structure of human acidic fibroblast growth factor and its interaction with heparin. , 1991, Archives of biochemistry and biophysics.

[20]  M. Goldfarb,et al.  Functions of fibroblast growth factors in vertebrate development. , 1996, Cytokine & growth factor reviews.

[21]  S. A. Marshall,et al.  Rational design and engineering of therapeutic proteins. , 2003, Drug discovery today.

[22]  V. Lin,et al.  Peripheral nerve grafts and aFGF restore partial hindlimb function in adult paraplegic rats. , 2002, Journal of neurotrauma.

[23]  Y. Kallberg,et al.  Prediction of Amyloid Fibril-forming Proteins* , 2001, The Journal of Biological Chemistry.

[24]  M. Redondo-Horcajo,et al.  Systemic administration of acidic fibroblast growth factor ameliorates the ischemic injury of the retina in rats , 1998, Neuroscience Letters.

[25]  Malgorzata Zakrzewska,et al.  Design of fully active FGF-1 variants with increased stability. , 2004, Protein engineering, design & selection : PEDS.

[26]  D. Ornitz,et al.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  J. Ware,et al.  Angiogenesis in ischemic heart disease , 1997, Nature Medicine.

[28]  David T. Jones,et al.  Protein superfamilles and domain superfolds , 1994, Nature.

[29]  J. Thornton,et al.  PROMOTIF—A program to identify and analyze structural motifs in proteins , 1996, Protein science : a publication of the Protein Society.

[30]  M. Jaye,et al.  Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation , 1994, Cell.

[31]  G. Giménez-Gallego,et al.  The complete amino acid sequence of human brain-derived acidic fibroblast growth factor. , 1986, Biochemical and biophysical research communications.

[32]  J. Isner,et al.  Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.

[33]  C. Pace,et al.  How to measure and predict the molar absorption coefficient of a protein , 1995, Protein science : a publication of the Protein Society.

[34]  Nobuyuki Itoh,et al.  Fibroblast growth factors , 2001, Genome Biology.

[35]  P. Cuevas,et al.  Acidic fibroblast growth factor rescues gerbil hippocampal neurons from ischemic apoptotic death. , 1998, Neurological research.

[36]  A. Rapak,et al.  Stimulation of proliferation of a human osteosarcoma cell line by exogenous acidic fibroblast growth factor requires both activation of receptor tyrosine kinase and growth factor internalization , 1996, Molecular and cellular biology.

[37]  S. Epstein,et al.  Effects of acidic fibroblast growth factor on normal and ischemic myocardium. , 1991, Circulation research.

[38]  D. Volkin,et al.  Effect of polyanions on the unfolding of acidic fibroblast growth factor. , 1993, Biochemistry.

[39]  N. Itoh,et al.  Evolution of the Fgf and Fgfr gene families. , 2004, Trends in genetics : TIG.

[40]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[41]  M M Santoro,et al.  A test of the linear extrapolation of unfolding free energy changes over an extended denaturant concentration range. , 1992, Biochemistry.

[42]  T A Einhorn,et al.  Growth Factor Regulation of Fracture Repair , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  K A Dill,et al.  Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.

[44]  A. Rapak,et al.  Translocation to Cytosol of Exogenous, CAAX-tagged Acidic Fibroblast Growth Factor (*) , 1995, The Journal of Biological Chemistry.

[45]  E. Edelman,et al.  Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. , 1998, American journal of physiology. Heart and circulatory physiology.

[46]  R. Vessella,et al.  Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. , 1998, Immunotechnology : an international journal of immunological engineering.

[47]  P. Y. Chou,et al.  Prediction of the secondary structure of proteins from their amino acid sequence. , 2006 .

[48]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[49]  I. Lax,et al.  Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? , 1995, Cell.

[50]  J. Wagner,et al.  Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half‐life , 1989, Journal of cellular physiology.

[51]  J. Thornton,et al.  A revised set of potentials for β‐turn formation in proteins , 1994 .

[52]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[53]  Bernhard Reuss,et al.  Fibroblast growth factors and their receptors in the central nervous system , 2003, Cell and Tissue Research.

[54]  Shaun K Olsen,et al.  Fibroblast Growth Factor (FGF) Homologous Factors Share Structural but Not Functional Homology with FGFs* , 2003, Journal of Biological Chemistry.

[55]  J. Temsamani,et al.  The use of cell-penetrating peptides for drug delivery. , 2004, Drug discovery today.

[56]  Andreas Plückthun,et al.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.

[57]  D. Rees,et al.  Three-dimensional structures of acidic and basic fibroblast growth factors. , 1993, Science.

[58]  J. Wells,et al.  Additivity of mutational effects in proteins. , 1990, Biochemistry.

[59]  S. Steinbacher,et al.  Sequence statistics reliably predict stabilizing mutations in a protein domain. , 1994, Journal of molecular biology.

[60]  M. Blaber,et al.  An atomic resolution structure for human fibroblast growth factor 1 , 2004, Proteins.

[61]  Anirban Kundu,et al.  Computational stabilization of human growth hormone , 2002, Protein science : a publication of the Protein Society.

[62]  S. Marqusee,et al.  Probing the high energy states in proteins by proteolysis. , 2004, Journal of molecular biology.

[63]  S. Hubbard,et al.  The structural aspects of limited proteolysis of native proteins. , 1998, Biochimica et biophysica acta.

[64]  M. Blaber,et al.  Alternative type I and I′ turn conformations in the β8/β9 β‐hairpin of human acidic fibroblast growth factor , 2002 .

[65]  S. A. Marshall,et al.  Designing proteins for therapeutic applications. , 2003, Current opinion in structural biology.

[66]  T. Imamura,et al.  Cell cycle-dependent nuclear localization of exogenously added fibroblast growth factor-1 in BALB/c 3T3 and human vascular endothelial cells. , 1994, Experimental cell research.

[67]  L. Buck,et al.  Enhancement of therapeutic protein in vivo activities through glycoengineering , 2003, Nature Biotechnology.

[68]  Claudio D. Stern,et al.  Patterning the Embryonic Axis FGF Signaling and How Vertebrate Embryos Measure Time , 2001, Cell.

[69]  Kirsten Sandvig,et al.  Dual mode of signal transduction by externally added acidic fibroblast growth factor , 1994, Cell.

[70]  Jeremy M. Berg,et al.  Thermodynamic β -sheet propensities measured using a zinc-finger host peptide , 1993, Nature.

[71]  T. Maciag,et al.  The heparin-binding (fibroblast) growth factor family of proteins. , 1989, Annual review of biochemistry.

[72]  S. Olsnes,et al.  Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. , 2003, Physiological reviews.

[73]  S. Venyaminov,et al.  Determination of Protein Secondary Structure , 1996 .

[74]  T. Maciag,et al.  Analysis of endogenous and exogenous nuclear translocation of fibroblast growth factor-1 in NIH 3T3 cells. , 1992, Biochemical and biophysical research communications.

[75]  T. Logan,et al.  Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a β‐trefoil , 2001, Protein science : a publication of the Protein Society.

[76]  K. Yokote,et al.  Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding , 1998, Oncogene.

[77]  H. Bussey,et al.  Heparin Overview and Issues , 2004, Pharmacotherapy.